A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (NCT04988295)
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) and amivantamab, carboplatin and pemetrexed (ACP) compared with carboplatin and pemetrexed (CP) in participants with locally advanced or metastatic epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution non-small cell lung cancer (NSCLC) after osimertinib failure. The purpose of the extension cohort is to further describe the safety and efficacy for the ACP-L dosing schedule versus ACP with additional data. After completion of the primary analysis, the study may eventually transition to an open-label extension (OLE) or long-term extension (LTE) phase during which participants will have the option to continue their assigned treatment.
Who can join: Review the eligibility criteria below.
Location: Southern Cancer Center, PC — Mobile, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (249 Sites)
Showing the first 25 of 249 sites.
- Southern Cancer Center, PC — Mobile, Alabama
- Arizona Oncology Associates — Tucson, Arizona
- City of Hope — Duarte, California
- Cedars Sinai Medical Center — Los Angeles, California
- University of California Irvine — Orange, California
- Rocky Mountain Cancer Centers — Colorado Springs, Colorado
- Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center — Fort Lauderdale, Florida
- University Cancer And Blood Center LLC — Athens, Georgia
- University of Mississippi Medical Center — Jackson, Mississippi
- Nebraska Cancer Specialists — Grand Island, Nebraska
- Astera Cancer Care — East Brunswick, New Jersey
- TriHealth Network — Cincinnati, Ohio
- Providence Portland Medical Center — Portland, Oregon
- Kaiser Permanente Northwest — Portland, Oregon
- Alliance Cancer Specialists — Horsham, Pennsylvania
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- Baptist Cancer Center — Memphis, Tennessee
- Texas Oncology-Medical City Dallas — Dallas, Texas
- Texas Oncology Baylor Charles A Sammons Cancer Center — Dallas, Texas
- Texas Oncology — Grapevine, Texas
- Oncology Consultants Texas — Houston, Texas
- Texas Oncology - Northeast — Longview, Texas
- University of Vermont Medical Center — Burlington, Vermont
- University of Virginia — Charlottesville, Virginia
- Virginia Cancer Specialists — Fairfax, Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Carcinoma, Non-Small-Cell Lung
- MYLUNG Consortium Study Protocol 2 — Daphne, Alabama
- A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) — Des Moines, Iowa
- THIO Sequenced With Cemiplimab in Advanced NSCLC — Birmingham, Alabama
- A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Duarte, California
- Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study — La Jolla, California
- A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) — Los Angeles, California
Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.